Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.

Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, Rufer N, Donda A, Zehn D, Jandus C, Romero P.

Cancer Immunol Res. 2019 Jun;7(6):1013-1024. doi: 10.1158/2326-6066.CIR-18-0504. Epub 2019 May 1.

PMID:
31043416
2.

Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.

Botelho NK, Tschumi BO, Hubbell JA, Swartz MA, Donda A, Romero P.

Front Immunol. 2019 Feb 26;10:294. doi: 10.3389/fimmu.2019.00294. eCollection 2019.

3.

Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development.

Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, Donda A, Gonzalez BJ, Jandus C, Bouzakri K, Pinget M, Boitard C, Romero P, Dotta F, Regazzi R.

Cell Metab. 2019 Feb 5;29(2):348-361.e6. doi: 10.1016/j.cmet.2018.09.011. Epub 2018 Oct 11.

PMID:
30318337
4.

Correction to: CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Sep 25;6(1):92. doi: 10.1186/s40425-018-0410-2.

5.

Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth.

Lasso P, Gomez-Cadena A, Urueña C, Donda A, Martinez-Usatorre A, Barreto A, Romero P, Fiorentino S.

Front Oncol. 2018 Aug 30;8:356. doi: 10.3389/fonc.2018.00356. eCollection 2018.

6.

CART cells are prone to Fas- and DR5-mediated cell death.

Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A.

J Immunother Cancer. 2018 Jul 13;6(1):71. doi: 10.1186/s40425-018-0385-z. Erratum in: J Immunother Cancer. 2018 Sep 25;6(1):92.

7.

PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.

Martínez-Usatorre A, Donda A, Zehn D, Romero P.

J Immunol. 2018 Jul 15;201(2):792-803. doi: 10.4049/jimmunol.1701644. Epub 2018 Jun 6.

8.
9.

Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients.

Murray T, Fuertes Marraco SA, Baumgaertner P, Bordry N, Cagnon L, Donda A, Romero P, Verdeil G, Speiser DE.

Front Immunol. 2016 Dec 12;7:573. doi: 10.3389/fimmu.2016.00573. eCollection 2016.

10.

Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model.

Gomez-Cadena A, Urueña C, Prieto K, Martinez-Usatorre A, Donda A, Barreto A, Romero P, Fiorentino S.

Cell Death Dis. 2016 Jun 2;7(6):e2243. doi: 10.1038/cddis.2016.134.

11.

Mammalian Target of Rapamycin Complex 2 Controls CD8 T Cell Memory Differentiation in a Foxo1-Dependent Manner.

Zhang L, Tschumi BO, Lopez-Mejia IC, Oberle SG, Meyer M, Samson G, Rüegg MA, Hall MN, Fajas L, Zehn D, Mach JP, Donda A, Romero P.

Cell Rep. 2016 Feb 9;14(5):1206-1217. doi: 10.1016/j.celrep.2015.12.095. Epub 2016 Jan 21.

12.

iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine.

Corgnac S, Perret R, Zhang L, Mach JP, Romero P, Donda A.

J Immunother Cancer. 2014 Nov 18;2(1):39. doi: 10.1186/s40425-014-0039-8. eCollection 2014.

13.

Mammalian target of rapamycin complex 1 orchestrates invariant NKT cell differentiation and effector function.

Zhang L, Tschumi BO, Corgnac S, Rüegg MA, Hall MN, Mach JP, Romero P, Donda A.

J Immunol. 2014 Aug 15;193(4):1759-65. doi: 10.4049/jimmunol.1400769. Epub 2014 Jul 11.

14.

Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity.

Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P.

Cancer Res. 2013 Nov 15;73(22):6597-608. doi: 10.1158/0008-5472.CAN-13-0875. Epub 2013 Sep 18.

15.

MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer.

Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.

Immunity. 2013 Apr 18;38(4):742-53. doi: 10.1016/j.immuni.2012.12.006.

16.

CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.

Corgnac S, Perret R, Derré L, Zhang L, Stirnemann K, Zauderer M, Speiser DE, Mach JP, Romero P, Donda A.

Cancer Immunol Immunother. 2013 Apr;62(4):747-60. doi: 10.1007/s00262-012-1381-7. Epub 2012 Dec 15.

17.

SITC 26th annual meeting--summary.

Romano E, Nardelli-Haefliger D, Donda A, Corgnac S, Romero P.

J Transl Med. 2012 May 23;10:105. doi: 10.1186/1479-5876-10-105.

18.

Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity.

Sierro SR, Donda A, Perret R, Guillaume P, Yagita H, Levy F, Romero P.

Eur J Immunol. 2011 Aug;41(8):2217-28. doi: 10.1002/eji.201041235. Epub 2011 May 27.

19.

Estrogen receptor regulates MyoD gene expression by preventing AP-1-mediated repression.

Pedraza-Alva G, Zingg JM, Donda A, Pérez-Martínez L.

Biochem Biophys Res Commun. 2009 Nov 13;389(2):360-5. doi: 10.1016/j.bbrc.2009.08.153. Epub 2009 Aug 31.

PMID:
19723510
20.

Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cells.

Schuler P, Contassot E, Irla M, Hugues S, Preynat-Seauve O, Beermann F, Donda A, French LE, Huard B.

Cancer Res. 2008 Oct 15;68(20):8410-8. doi: 10.1158/0008-5472.CAN-08-0809.

21.

Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice.

Stirnemann K, Romero JF, Baldi L, Robert B, Cesson V, Besra GS, Zauderer M, Wurm F, Corradin G, Mach JP, Macdonald HR, Donda A.

J Clin Invest. 2008 Mar;118(3):994-1005. doi: 10.1172/JCI33249.

22.

TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses.

Heer AK, Shamshiev A, Donda A, Uematsu S, Akira S, Kopf M, Marsland BJ.

J Immunol. 2007 Feb 15;178(4):2182-91.

23.

Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.

Cesson V, Stirnemann K, Robert B, Luescher I, Filleron T, Corradin G, Mach JP, Donda A.

Clin Cancer Res. 2006 Dec 15;12(24):7422-30.

24.

MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells.

Germain C, Larbouret C, Cesson V, Donda A, Held W, Mach JP, Pèlegrin A, Robert B.

Clin Cancer Res. 2005 Oct 15;11(20):7516-22.

26.

A new aspect in glycolipid biology: glycosphingolipids as antigens recognized by T lymphocytes.

De Libero G, Donda A, Gober HJ, Manolova V, Mazorra Z, Shamshiev A, Mori L.

Neurochem Res. 2002 Aug;27(7-8):675-85. Review.

PMID:
12374202
27.

Presentation of the same glycolipid by different CD1 molecules.

Shamshiev A, Gober HJ, Donda A, Mazorra Z, Mori L, De Libero G.

J Exp Med. 2002 Apr 15;195(8):1013-21.

28.

Immunity to glycolipid antigens in microbial infections.

De Libero G, Donda A, Mori L, Manolova V, Shamshiev A.

J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):249-56. Review.

PMID:
11693433
29.

Ligand-independent assembly of recombinant human CD1 by using oxidative refolding chromatography.

Altamirano MM, Woolfson A, Donda A, Shamshiev A, Briseño-Roa L, Foster NW, Veprintsev DB, De Libero G, Fersht AR, Milstein C.

Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3288-93.

30.

Locally inducible CD66a (CEACAM1) as an amplifier of the human intestinal T cell response.

Donda A, Mori L, Shamshiev A, Carena I, Mottet C, Heim MH, Beglinger C, Grunert F, Rochlitz C, Terracciano L, Jantscheff P, De Libero G.

Eur J Immunol. 2000 Sep;30(9):2593-603.

31.

The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides.

Shamshiev A, Donda A, Prigozy TI, Mori L, Chigorno V, Benedict CA, Kappos L, Sonnino S, Kronenberg M, De Libero G.

Immunity. 2000 Aug;13(2):255-64.

32.

Self glycolipids as T-cell autoantigens.

Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G.

Eur J Immunol. 1999 May;29(5):1667-75.

33.

TTF-2 does not appear to be a key mediator of the effect of cyclic AMP on thyroglobulin gene transcription in primary cultured dog thyrocytes.

Pouillon V, Pichon B, Donda A, Christophe D.

Biochem Biophys Res Commun. 1998 Jan 14;242(2):327-31.

PMID:
9446794
35.

Functional inactivation in the whole population of human V gamma 9/V delta 2 T lymphocytes induced by a nonpeptidic antagonist.

Bürk MR, Carena I, Donda A, Mariani F, Mori L, De Libero G.

J Exp Med. 1997 Jan 6;185(1):91-7.

36.

Thymocytes control the CD4 gene differently from mature T lymphocytes.

Uematsu Y, Donda A, De Libero G.

Int Immunol. 1997 Jan;9(1):179-87.

PMID:
9043959
37.

Identification and characterization of a human CD4 silencer.

Donda A, Schulz M, Bürki K, De Libero G, Uematsu Y.

Eur J Immunol. 1996 Feb;26(2):493-500.

PMID:
8617322
38.

Human, bovine, canine and rat thyroglobulin promoter sequences display species-specific differences in an in vitro study.

Donda A, Javaux F, Van Renterghem P, Gervy-Decoster C, Vassart G, Christophe D.

Mol Cell Endocrinol. 1993 Jan;90(2):R23-6.

PMID:
8388339
39.

Identification of a transcriptional enhancer upstream from the bovine thyroglobulin gene.

Christophe-Hobertus C, Donda A, Javaux F, Vassart G, Christophe D.

Mol Cell Endocrinol. 1992 Oct;88(1-3):31-7.

PMID:
1459338
40.

Functional role of TTF-1 binding sites in bovine thyroglobulin promoter.

Javaux F, Bertaux F, Donda A, Francis-Lang H, Vassart G, DiLauro R, Christophe D.

FEBS Lett. 1992 Apr 6;300(3):222-6.

41.

Isolation and characterization of the canine thyroglobulin gene promoter region.

Donda A, Vassart G, Christophe D.

Biochim Biophys Acta. 1991 Oct 8;1090(2):235-7.

PMID:
1932116
42.
43.

Sex steroids modulate the pituitary parameters involved in the regulation of TSH secretion in the rat.

Donda A, Reymond F, Rey F, Lemarchand-Béraud T.

Acta Endocrinol (Copenh). 1990 May;122(5):577-84.

PMID:
2162122
44.

Influence of age on the control of thyrotropin secretion by thyrotropin-releasing hormone in the male rat.

Donda A, Reymond MJ, Lemarchand-Béraud T.

Neuroendocrinology. 1989 Apr;49(4):389-94.

PMID:
2497398
45.

Aging alters the activity of 5'-deiodinase in the adenohypophysis, thyroid gland, and liver of the male rat.

Donda A, Lemarchand-Béraud T.

Endocrinology. 1989 Mar;124(3):1305-9.

PMID:
2917513
46.

Neuroendocrine aspects of aging: experimental data.

Reymond MJ, Donda A, Lemarchand-Béraud T.

Horm Res. 1989;31(1-2):32-8. Review.

PMID:
2656467
47.

Influence of sex and age on T3 receptors and T3 concentration in the pituitary gland of the rat: consequences on TSH secretion.

Donda A, Reymond MJ, Zürich MG, Lemarchand-Béraud T.

Mol Cell Endocrinol. 1987 Nov;54(1):29-34.

PMID:
3119396
48.

Mare lactotransferrin: purification, analysis and N-terminal sequence determination.

Jollès J, Donda A, Amiguet P, Jollès P.

FEBS Lett. 1984 Oct 15;176(1):185-8.

Supplemental Content

Support Center